Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Blood (2023) 142 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2023-181142

Published: 2023

Journal Articles

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Blood (2023) 142 (Supplement 1): 5877.

https://doi.org/10.1182/blood-2023-182976

Published: 2023

Journal Articles

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Blood (2021) 138 (Supplement 1): 216.

https://doi.org/10.1182/blood-2021-150958

Published: 2021

Journal Articles

Multidimensional Vascular Evaluation in Patients Treated with Tyrosine Kinase Inhibitors (TKIs): From Plaque Formation to Evolution and Follow up on 150 Patients

Elisabetta Abruzzese, MD, Rossana Gloria, MD, Andrea Siani, MD, Carla Mazzone, MD, Matteo Molica, MD, Teresa Dentamaro, MD, Luca Cupelli, MD, Malgorzata Monika Trawinska, MD, Paolo De Fabritiis, MD

Blood (2020) 136 (Supplement 1): 54.

https://doi.org/10.1182/blood-2020-142732

Published: 2020

Journal Articles

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

Blood (2019) 134 (Supplement_1): 117.

https://doi.org/10.1182/blood-2019-125562

Published: 2019

Journal Articles

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study

Samantha Pozzi, MD, Stefania Badiali, MS, Alessandro Corso, MD, Pellegrino Musto, MD, Attilio Guarini, MD, Carla Minoia, MD, Donatella Vincelli, MD, Roberto Ria, MD, Luciano Masini, MD, Giovanni Quarta, MD, Massimo Gentile, MD, Carla Mazzone, MD, Antonio Palumbo, MD, Fortunato Morabito, MD, Stefano Sacchi, MD

Blood (2013) 122 (21): 3212.

https://doi.org/10.1182/blood.V122.21.3212.3212

Published: 2013

Journal Articles

A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma

Stefano Sacchi, Samantha Pozzi, Stefania Badiali, Attilio Guarini, Carla Mazzone, Alessandro Corso, Donatella Vincelli, Luciano Masini, Pellegrino Musto, Roberto Ria, Giovanni Quarta, Antonio Lazzaro, Antonio Palumbo, Fortunato Morabito

Blood (2012) 120 (21): 1851.

https://doi.org/10.1182/blood.V120.21.1851.1851

Published: 2012

Journal Articles

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

Blood (2011) 118 (22): 5759–5766.

https://doi.org/10.1182/blood-2011-05-353995

Published: 2011

Journal Articles

Simultaneous Detection of Genomic Rearrangements In Myelodysplastic Syndromes (MDS) with the Multiplex Ligation-Dependent Probe Amplification (MLPA) Assay

Oronzo Scarciolla, MD, PhD, Alberto Fragasso, MD, Clara Mannarella, MD, Angela Ciancio, MD, Rosa Anna Cifarelli, Massimo Gentile, MD, Catia Dininno, Carla Mazzone, MD, Anna Grazia Recchia, PhD, Pasquale Servillo, Ernesto Vigna, MD, Paola Casieri, Lisa Anelli, Fortunato Morabito, MD, Giorgina Specchia, MD

Blood (2010) 116 (21): 1863.

https://doi.org/10.1182/blood.V116.21.1863.1863

Published: 2010

Journal Articles

A Pilot Study of Lenalidomide and Dexamethasone as First Line Therapy in Patients with Primary Plasma Cell Leukemia.

Pellegrino Musto, Maria Teresa Petrucci, Fortunato Morabito, Francesco Nobile, Fiorella D'Auria, Rosa Lerose, Anna Sparano, Antonia Zonno, Vincenzo Callea, Anna Levi, Carla Mazzone, Giuseppe Pietrantuono, Maria Carmen Martorelli, Antonino Neri, Paola Omedè, Sara Bringhen, Michele Cavo, Mario Boccadoro, Antonio Palumbo

Blood (2009) 114 (22): 4951.

https://doi.org/10.1182/blood.V114.22.4951.4951

Published: 2009

Journal Articles

Definition of a Prognostic Scoring System for Predicting Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia.

Fortunato Morabito, MD, Giovanna Cutrona, PhD, Massimo Gentile, MD, Serena Matis, PhD, Monica Colombo, PhD, Eugenio Lucia, MD, Mauro Spriano, MD, Edoardo Rossi, MD, Vincenzo Callea, MD, Caterina Stelitano, MD, Carla Mazzone, MD, Ernesto Vigna, MD, Carlo Gentile, MD, Gianluca Festini, MD, Antonino Neri, MD, Simonetta Zupo, PhD, Stefano Molica, MD, Nicholas Chiorazzi, MD, Manlio Ferrarini, MD

Blood (2006) 108 (11): 2328.

https://doi.org/10.1182/blood.V108.11.2328.2328

Published: 2006

Journal Articles

Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia

Blood (2006) 108 (3): 853–861.

https://doi.org/10.1182/blood-2005-12-4986

Published: 2006

Journal Articles

The Kinetics of Reduction of Minimal Residual Disease Impacts on Duration of Survival and Response of Adult Patients with Acute Myeloid Leukemia.

Adriano Venditti, MD, Luca Maurillo, MD, Francesco Buccisano, MD, Giovanni Del Poeta, MD, Carla Mazzone, MD, Benedetta Neri, MD, Francesco Lo Coco, MD, Sergio Amadori, MD

Blood (2005) 106 (11): 2358.

https://doi.org/10.1182/blood.V106.11.2358.2358

Published: 2005

Journal Articles

Monitoring of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia Using Peripheral Blood (PB) as an Alternative Source to Bone Marrow (BM).

Luca Maurillo, MD, Francesco Buccisano, MD, Benedetta Neri, MD, Carla Mazzone, MD, Giovanni Del Poeta, MD, Licia Ottaviani, MD, Pasquale Niscola, MD, Ilaria Del Principe, MD, Anna Tamburini, MD, Maria Irno Consalvo, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2005) 106 (11): 2361.

https://doi.org/10.1182/blood.V106.11.2361.2361

Published: 2005

Journal Articles

Clinical Relevance of Spontaneous Apoptosis Is Independent from Multidrug Resistance in Acute Myeloid Leukemia (AML).

Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Adriano Venditti, MD, Francesco Buccisano, MD, Luca Maurillo, MD, Carla Mazzone, MD, Benedetta Neri, MD, Maria Irno Consalvo, PhD, Antonio Bruno, PhD, Francesco Lo Coco, MD, Valter Gattei, MD, Sergio Amadori, MD

Blood (2005) 106 (11): 333.

https://doi.org/10.1182/blood.V106.11.333.333

Published: 2005

Journal Articles

Spontaneous Apoptosis and Proliferation Predict Disease Progression within ZAP-70 Negative B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Pasquale Niscola, MD, Luca Maurillo, MD, Adriano Venditti, MD, Francesco Buccisano, MD, Maria Irno Consalvo, PhD, Carla Mazzone, MD, Paola Panetta, PhD, Massimo Degan, PhD, Irene Pasqua, PhD, Antonio Bruno, PhD, Valter Gattei, MD, Francesco Lo Coco, MD, Sergio Amadori, MD

Blood (2005) 106 (11): 1197.

https://doi.org/10.1182/blood.V106.11.1197.1197

Published: 2005

Journal Articles

The Kinetic of Reduction of Minimal Residual Disease Impacts on duration of Response snd Survival of Patients with Acute Myeloid Leukemia.

Francesco Buccisano, MD, Luca Maurillo, MD, Giovanni Del Poeta, MD, Anna Tamburini, MD, Maria Christina Cox, MD, Maria Ilaria Del Principe, MD, Maria Irno Consalvo, PhD, Carla Mazzone, MD, Benedetta Neri, MD, Licia Ottaviani, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2004) 104 (11): 399.

https://doi.org/10.1182/blood.V104.11.399.399

Published: 2004

Journal Articles

Clinical Significance of Apoptosis Is Independent from Proliferation in Acute Myeloid Leukemia (AML).

Giovanni Del Poeta, M.D., Maria Ilaria Del Principe, M.D., Adriano Venditti, M.D., Luca Maurillo, M.D., Francesco Buccisano, M.D., Maria Irno Consalvo, Ph.D., Carla Mazzone, M.D., Maria Christina Cox, M.D., Antonio Bruno, M.D., Francesco Lo Coco, M.D., Sergio Amadori, M.D.

Blood (2004) 104 (11): 198.

https://doi.org/10.1182/blood.V104.11.198.198

Published: 2004

Journal Articles

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML): Presented in part at the 42nd annual meeting of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. 46

Giovanni Del Poeta, Adriano Venditti, Maria Ilaria Del Principe, Luca Maurillo, Francesco Buccisano, Anna Tamburini, Maria Christina Cox, Annibale Franchi, Antonio Bruno, Carla Mazzone, Paola Panetta, Giovanna Suppo, Mario Masi, Sergio Amadori

Blood (2003) 101 (6): 2125–2131.

https://doi.org/10.1182/blood-2002-06-1714

Published: 2003

NARROW

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Multidimensional Vascular Evaluation in Patients Treated with Tyrosine Kinase Inhibitors (TKIs): From Plaque Formation to Evolution and Follow up on 150 Patients

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study

A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

Simultaneous Detection of Genomic Rearrangements In Myelodysplastic Syndromes (MDS) with the Multiplex Ligation-Dependent Probe Amplification (MLPA) Assay

A Pilot Study of Lenalidomide and Dexamethasone as First Line Therapy in Patients with Primary Plasma Cell Leukemia.

Definition of a Prognostic Scoring System for Predicting Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia.

Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia

The Kinetics of Reduction of Minimal Residual Disease Impacts on Duration of Survival and Response of Adult Patients with Acute Myeloid Leukemia.

Monitoring of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia Using Peripheral Blood (PB) as an Alternative Source to Bone Marrow (BM).

Clinical Relevance of Spontaneous Apoptosis Is Independent from Multidrug Resistance in Acute Myeloid Leukemia (AML).

Spontaneous Apoptosis and Proliferation Predict Disease Progression within ZAP-70 Negative B-Cell Chronic Lymphocytic Leukemia (B-CLL).

The Kinetic of Reduction of Minimal Residual Disease Impacts on duration of Response snd Survival of Patients with Acute Myeloid Leukemia.

Clinical Significance of Apoptosis Is Independent from Proliferation in Acute Myeloid Leukemia (AML).

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML): Presented in part at the 42nd annual meeting of the American Society of Hematology, San Francisco, CA, December 1-5, 2000. 46

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only